MedTrace Logo

Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm

NCT04551014 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2022-09-01

Study results available
· View outcomes & findings →

Summary

The focus of the study is to evaluate impact of submucosal injection of EverLift in achieving complete resection during polypectomy of polyps 4-9mm during colonoscopy.

Conditions

  • Colo-rectal Cancer
  • Polyp of Colon
  • Adenomatous Polyp of Colon

Interventions

DEVICE

Use of EverLift

Use of EverLift for submucosal injection prior to polypectomy

DEVICE

Without use of EverLift

Without use of EverLift for submucosal injection prior to polypectomy

Sponsors & Collaborators

Principal Investigators

  • Shai Friedland, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-16
Primary Completion
2021-05-31
Completion
2021-07-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04551014 on ClinicalTrials.gov